Madrigal Q1 Revenue Jumps 127% to $311M, Rezdiffra Achieves Blockbuster Status
MDGL sits 90% above its 52-week low of $265.
Summary
Madrigal Pharmaceuticals reported robust first-quarter 2026 financial results, with net revenues surging 127% year-over-year to $311.3 million. The company highlighted that its key drug, Rezdiffra, has achieved blockbuster status on a trailing-12-month net sales basis, driven by broad physician adoption and high patient demand. This strong performance reinforces management's confidence in Rezdiffra's growth expectations for 2026 and its leadership in the rapidly expanding MASH market. The report also provided updates on pipeline expansion, including the recently announced licensing agreement for ARO-PNPLA3 from Arrowhead, which targets a significant portion of MASH patients. Investors will be watching for continued sales momentum for Rezdiffra and further developments from its expanded MASH pipeline.
At the time of this announcement, MDGL was trading at $503.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.5B. The 52-week trading range was $265.00 to $615.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.